公开(公告)号：US20240124546A1

公开(公告)日：2024-04-18

申请号：US18323722

申请日：2023-05-25

申请人： CytomX Therapeutics, Inc.

发明人： Sayantan MITRA ,  Nicole G. LAPUYADE ,  Hikmat Haizar ASSI ,  Madan M. PAIDHUNGAT ,  Dylan L. DANIEL ,  Erwan LE SCOLAN ,  Walter A. BOGDANOFF ,  Na CAI ,  Hsin WANG ,  Alexey Yevgenyevich BEREZHNOY

IPC分类号： C07K14/56 ,  C07K14/565 ,  C07K14/57

CPC分类号： C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  C07K2319/30 ,  C07K2319/50 ,  C07K2319/70

摘要： Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

公开(公告)号：US20220306717A1

公开(公告)日：2022-09-29

申请号：US17696222

申请日：2022-03-16

申请人： CytomX Therapeutics, Inc.

发明人： Sayantan MITRA ,  Nicole G. LAPUYADE ,  Hikmat Haizar ASSI ,  Madan M. PAIDHUNGAT ,  Dylan L. DANIEL ,  Erwan LE SCOLAN ,  Walter A. BOGDANOFF ,  Na CAI ,  Hsin WANG ,  Alexey Yevgenyevich BEREZHNOY

IPC分类号： C07K14/56 ,  C07K14/565 ,  C07K14/57

摘要： Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.